A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behcet Disease

Trial Profile

A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behcet Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Behcet's syndrome
  • Focus Therapeutic Use
  • Acronyms STELABEC
  • Most Recent Events

    • 08 Nov 2017 Planned End Date changed from 1 Jan 2019 to 1 Apr 2020.
    • 08 Nov 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Apr 2019.
    • 08 Nov 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top